A Study of YL202 in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Aug 31, 2026 → Jan 31, 2027
See other at-risk trials from MediLink Therapeutics (Suzhou) Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 31, 2026 to Jan 31, 2027
    • Eligibility criteria expanded, about 40 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 15, 2025 to Aug 4, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
Trial Details
NCT Number NCT07202364
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions
(from sponsor)		 Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
Related terms Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Uterine Cervical Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov